UNSPSC 51162601: Alloclamide

This classification denotes an antitussive agent with the molecular formula C16H23ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) H7B263Z7AQ, chemically known as benzamide, 4-chloro-n-(2-(diethylamino)ethyl)-2-(2-propenyloxy)- (9ci) but more generally known as alloclamide, which bears US NIH Compound Identifier 71837. Alloclamide comes in forms base and hydrochloride. European Medicines Agency schedules Alloclamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05335MIG.

UNSPSC 51162601 Alloclamide is a Commodity code under which state and local governments procure pharmaceutical products and medical supplies, specifically naloxone, drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products for community health, public safety, and facility operations. The issuing bodies include county health departments and state-administered cooperative purchasing alliances. Seminole County, Florida procured naloxone and safe drug deactivation systems through an IFB, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities. The scope of work involves direct pharmaceutical procurement with requirements for cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, FDA product validation, specific insurance coverage including commercial general liability ranging from $2,000,000 to $5,000,000, and E-Verify employment verification.

Recent opportunities show activity concentrated in Florida and Minnesota. Seminole County's IFB60459723LAS, posted June 30, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the bid deadline was July 26, 2023. MMCAP's RFP S1070000015802, posted January 20, 2026, established multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The MMCAP RFP weighted price competitiveness at 75 percent of evaluation and required vendor participation in electronic data interchange systems and compliance with administrative fee data format requirements. Neither solicitation named explicit set-aside designations for disadvantaged enterprises.